Hui Li

US Patent:

20100332499, Dec 30, 2010

Filed:

Jun 26, 2009

Appl. No.:

12/493097

Inventors:

Yufei Pan - North Brunswick NJ, US
Hui Li - Edison NJ, US
Justin Sarma - New York NY, US
David Soukal - Bothell WA, US
Alessio Signorini - Boulder CO, US
Apostolos Gerasoulis - Edison NJ, US
Tomasz Imielinski - Princeton NJ, US

Assignee:

IAC SEARCH & MEDIA, INC. - New York NY

International Classification:

G06F 17/30

US Classification:

707759, 707769

Abstract:

In a method for a direct answer for search, a search query is received over a network, one or more answer candidate snippets for the search query are received, with an answer candidate snippet having at least a portion of content available over the network for an answer candidate, one or more answer entities are determined within a selected answer candidate snippet, a frequency of the one or more answer entities found within the one or more answer candidate snippets for the search query is determined, a confidence score is adjusted for the selected answer candidate in accordance with the frequency of the one or more answer entities found within the one or more answer candidate snippets, and at least one answer candidate snippet is sent for a response to the search query.

US Patent:

20220195407, Jun 23, 2022

Filed:

May 7, 2020

Appl. No.:

17/609244

Inventors:

- Durham NC, US
Hui Li - Apex NC, US

Assignee:

Precision BioSciences, Inc. - Durham NC

International Classification:

C12N 9/22
C12N 15/10
C12N 15/86

Abstract:

The invention provides engineered meganucleases, derived from I-Crel, which have substitutions at particular positions that increase the activity of the nucleases for recognition sequences containing certain center sequences. The invention also provides methods of cleaving double-stranded DNA using such engineered meganucleases. The invention further provides methods for improving the activity of engineered meganucleases for recognition sequences containing certain center sequences.

US Patent:

20210113616, Apr 22, 2021

Filed:

Apr 11, 2019

Appl. No.:

17/046761

Inventors:

- Durham NC, US
Janel Lape - Wake Forest NC, US
Hui Li - Apex NC, US
Jochen Genschel - Raleigh NC, US

Assignee:

Precision BioSciences, Inc. - Durham NC

International Classification:

A61K 35/17
C12N 9/22
C12N 15/86
C07K 14/725

Abstract:

The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the first exon of the human T cell receptor (TCR) alpha constant region gene. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced (i.e., increased) specificity or efficiency of cleavage, when compared to the first-generation meganuclease TRC 1-2x.87EE. The present invention also encompasses methods of using such engineered nucleases to make genetically-modified cells, and the use of such cells in a pharmaceutical composition and in methods for treating diseases, such as cancer.

US Patent:

20210017171, Jan 21, 2021

Filed:

Jun 26, 2020

Appl. No.:

16/914209

Inventors:

- South San Francisco CA, US
Chengguo DONG - Staten Island NY, US
Timothy HOM - Sunnyvale CA, US
Lan JIANG - Foster City CA, US
Katerina LEFTHERIS - San Mateo CA, US
Hui LI - Santa Clara CA, US
Manuel MUNOZ - Vallejo CA, US
Maureen REILLY - Burlingame CA, US
Yajun ZHENG - Foster City CA, US

International Classification:

C07D 471/04
C07D 519/00

Abstract:

The invention relates to compounds of formula (A) and formula (I):or a salt thereof, wherein R, R, R, R, R, R, R, R, R, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

US Patent:

20200352942, Nov 12, 2020

Filed:

Apr 8, 2020

Appl. No.:

16/843824

Inventors:

- South San Francisco CA, US
Chengguo DONG - Staten Island NY, US
Timothy HOM - Sunnyvale CA, US
Lan JIANG - Foster City CA, US
Katerina LEFTHERIS - San Mateo CA, US
Hui LI - Santa Clara CA, US
Manuel MUNOZ - Vallejo CA, US
Maureen REILLY - Burlingame CA, US
Yajun ZHENG - Foster City CA, US
Martin DECARIS - Oakland CA, US
Scott TURNER - Oakland CA, US

International Classification:

A61K 31/5025
A61K 31/502
A61K 31/4375
A61K 9/00
A61P 11/00

Abstract:

The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I):or a salt thereof, wherein R, R, R, R, R, R, R, R, R, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

US Patent:

20190338263, Nov 7, 2019

Filed:

Apr 11, 2019

Appl. No.:

16/381668

Inventors:

- Durham NC, US
Janel Lape - Wake Forest NC, US
Victor Bartsevich - Durham NC, US
Hui Li - Apex NC, US

Assignee:

Precision BioSciences, Inc. - Durham NC

International Classification:

C12N 9/22
C12N 15/86
A61K 9/16
A61K 47/69

Abstract:

The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced specificity and/or efficiency of indel formation, when compared to the first-generation meganuclease HBV 11-12x.26. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or hepatocellular carcinoma.

US Patent:

20190276449, Sep 12, 2019

Filed:

Mar 7, 2019

Appl. No.:

16/296194

Inventors:

- South San Francisco CA, US
Chengguo DONG - Staten Island NY, US
Timothy HOM - Sunnyvale CA, US
Lan JIANG - Foster City CA, US
Katerina LEFTHERIS - San Mateo CA, US
Hui LI - Santa Clara CA, US
Manuel MUNOZ - Vallejo CA, US
Maureen REILLY - Burlingame CA, US
Yajun ZHENG - Foster City CA, US

International Classification:

C07D 471/04
C07D 519/00

Abstract:

The invention relates to compounds of formula (A) and formula (I):or a salt thereof, wherein R, R, R, R, R, R, R, R, R, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).